Dr Caroline Wilson, former principal scientist at the North East Innovation Lab, has been appointed to the role of commercial business manager.

The British In Vitro Diagnostics Association (BIVDA) has today launched a new independent whitepaper which examines the UK genomics landscape, with a focus on patient access to genomic testing.

The British In Vitro Diagnostics Association (BIVDA) commissioned the University of Nottingham to produce an independent White Paper examining the UK Government’s procurement of Covid-19 tests during the pandemic, which has been released today.

Digital clinical diagnostics and diabetes home testing provider Digostics and University Hospital Southampton NHS Foundation Trust (UHS) announced today a partnership that will see expectant mothers under the care of UHS maternity services become the first, anywhere in the world, to access ground-breaking new remote testing technology designed to improve screening for gestational diabetes mellitus (GDM).

Oxford Cancer Biomarkers Ltd (OCB), a leader in AI-driven, precision cancer diagnostics, has successfully closed its latest investment round.

Fast MDx is the first fully automated, high-throughput, near-patient testing system. It can detect many pathogens with unrivalled speed without the need for expensive biosecure laboratories. Developed by London-based social enterprise company Fast MDx, the eponymous testing system cuts the typical 24 to 48 hour waiting time to just one to two hours.

The North East Innovation Lab, part of Newcastle Hospitals has achieved a major milestone with accreditation to an international standard. The lab has been awarded accreditation by UKAS to ISO 15189 for SARS-CoV-2 testing which assesses not only the testing carried out by the lab, but also the quality management system required to ensure the laboratory operates to the highest standards.

Oxford Cancer Biomarkers (OCB) and OncoHelix today announce a new partnership to offer OCB’s advanced genetic test in Canada for screening and detection of people at risk for colorectal cancer.

The Department of Health and Social Care published the first strategy for medical technology today. The British In Vitro Diagnostics Association (BIVDA) welcomes this as another step forward to achieving wider use of the essential diagnostic tests and enabling technology which can really support better healthcare for patients and save resource for the NHS.

In this blog, Doris-Ann examines the pandemic’s legacy of normalising diagnostic testing and how we should use this opportunity to be more health aware as a society.